RECCE®327 Topical Gel Study for the clinical indication of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

Acute bacterial skin infections — including infected wounds, abscesses, and infected diabetic foot ulcers — can be difficult to treat, particularly as more bacteria develop resistance to common antibiotics. RECCE 327 is a novel topical gel antibiotic with a completely different mechanism of action from existing antibiotics, making it potentially effective against resistant bacteria. This study is the first step in evaluating whether this gel is safe, how it is absorbed by the body, and whether it can treat skin infections effectively. Up to 30 participants with acute bacterial skin and skin structure infections will apply RECCE 327 gel once daily to their wound for seven days. Safety and wound healing will be assessed throughout, with the possibility of a further seven days of treatment. The study can be conducted in either an outpatient or inpatient setting. Adults aged 18 or older with an acute bacterial skin infection — including diabetic foot ulcers with an open wound — may be eligible. Women of childbearing potential must use effective contraception. People who are pregnant or breastfeeding, have serious underlying medical conditions, are currently in another clinical trial, have wounds with exposed tendons or bone, or cannot apply dressings themselves (without a carer) are not eligible. The study is run by Recce Pharmaceuticals Limited.